Over the last 12 months, Colgate-Palmolive shares are down 16%, while the stock is down 25% from its 52-week high level as well. From its all-time high of ₹3,893 in October 2024, the stock has declined 45%.
The company has reported slower growth than its peers in the last few years. Colgate-Palmolive’s inverted duty structure, along with competition has impacted its margins.
| Quarter | Sales Growth (%) |
| Q3 FY25 | 4.7 |
| Q4 FY25 | -1.8 |
| Q1 FY26 | -4.2 |
| Q2 FY26 | -6.1 |
| Q3 FY26 | 1.66 |
It saw early signs of pick-up in January led by strong performance in the premium segment. The company expects the growth momentum to accelerate going forward.
The stock is valued at 38 times its estimated price-to-earnings ratio for FY27, which is lower than its 10-year historical average of 41 times.
Of the 33 analysts who have coverage on the stock, eight have ‘buy’ ratings, 12 have ‘hold’ ratings and 13 have ‘sell’ ratings.
ICICI Securities has the lowest price target of ₹1,800 per share, implying a potential downside of 18%, while Nuvama has the highest price target of ₹2,740 per share, an upside potential of 24.6%.
Shares of Colgate-Palmolive were down 6.5% at ₹2,056.2 apiece at 3:20 PM on Wednesday.
Also Read: Polycab warns of mid-single digit near-term volume growth but medium-term outlook positive
